Applying the Center for Medical Technology Policy’s (CMTP) Chain of Evidence for Clinical Utility to Prolaris, a Prognostic Prostate Cancer Test Developed by Myriad Genetic Laboratories
The CMTP in 2013 established best practices for generating evidence of clinical utility. Through its “Chain-of-Evidence” guidance, CMTP integrates analytic and clinical validity with an expanded definition of clinical utility, demonstrating that a diagnostic test can improve patient health outcomes, as well as quality of life and cost effectiveness.
Using the Prolaris prostate cancer prognostic test, we employ the CMTP chain-of-evidence format to demonstrate how it can be used to broaden clinical utility discussions between payers and providers beyond the traditional framework, thus facilitating a more rapid adoption of new technologies that improve member health and save health care dollars.
Download White Paper